Avenue Therapeutics Reports $695,000 Net Loss in Q1 2026, Improves from $1.9 Million Loss in Q1 2025

Avenue Therapeutics, Inc. reported a net loss of approximately $695,000 for the first quarter of 2026, a significant improvement compared to a net loss of $1.9 million during the same period in 2025. The company's accumulated deficit now stands at $106.2 million. Total operating expenses decreased to $714,000, down from $1.9 million in the prior year, primarily due to reduced research and development costs, which fell by 51% to $200,000, and a 66% reduction in general and administrative expenses to $514,000. The decrease in expenses reflects the company's strategic focus on cost management as it continues to develop its product candidates.

In terms of financial position, Avenue Therapeutics reported total assets of $2.5 million as of March 31, 2026, down from $2.9 million at the end of 2025. The company’s cash and cash equivalents decreased to $2.4 million from $2.9 million, while total liabilities increased to $1.3 million from $1.1 million, primarily due to higher accounts payable and accrued expenses. The company’s stockholders’ equity also declined to $1.2 million from $1.8 million, reflecting the net loss incurred during the quarter.

Strategically, Avenue Therapeutics entered into a significant licensing agreement with Duke University in February 2026, acquiring exclusive rights to develop ATX-04, a treatment for lysosomal storage diseases. The agreement includes upfront payments of approximately $19,000 and potential milestone payments totaling $15.6 million, along with tiered royalties on future net sales. This move is part of Avenue's broader strategy to expand its product pipeline, which also includes intravenous tramadol for post-operative pain management.

Operationally, Avenue Therapeutics is preparing for a pivotal study design for ATX-04, following promising results from a Phase I/II clinical study. The company is also in discussions with the FDA regarding a Phase 3 safety study for IV tramadol, which aims to assess the risk of respiratory depression. However, Avenue faces challenges in securing additional funding to support these initiatives, as it has indicated substantial doubt about its ability to continue as a going concern without further capital. The company plans to explore various financing options, including equity or debt offerings, to sustain its operations and product development efforts.

Looking ahead, Avenue Therapeutics anticipates continued operating losses as it invests in research and development. The company is actively seeking additional capital to fund its operations and advance its product candidates through clinical development and regulatory approval. The management remains cautious about the future, emphasizing the need for strategic partnerships and financing to ensure the viability of its business model.